Inhibition of brain metastasis by blocking MAPK12 driver kinase functions
通过阻断 MAPK12 驱动激酶功能抑制脑转移
基本信息
- 批准号:10172862
- 负责人:
- 金额:$ 43.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-06-01 至 2022-11-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectAnimalsAreaBiological AssayBrainBreast Cancer CellBreast Cancer PatientBreast Cancer PreventionBreast Cancer TreatmentBreast Cancer cell lineBreast Cancer therapyBreast cancer metastasisCancer PatientCarotid ArteriesCellsChemicalsCitric Acid CycleClinicClinicalClinical TrialsDataDiagnosisDiseaseDisseminated Malignant NeoplasmEarly InterventionEnergy-Generating ResourcesFDA approvedFamilyFutureGenerationsGlucoseGoalsGrowthHumanImmunocompetentIncidenceLibrariesMAP Kinase GeneMAPK12 geneMDA MB 231Malignant NeoplasmsMediatingMetabolismMetastatic breast cancerMetastatic malignant neoplasm to brainMetastatic toMitochondriaModelingMusNeoplasm MetastasisNude MicePathway interactionsPatientsPharmacotherapyPhosphotransferasesPlayPopulationPreventionPrimary NeoplasmQuality of lifeRecurrenceRefractoryResearchRoleSignal PathwaySignal TransductionSystemic diseaseTestingTherapeutic AgentsTissuesTranslatingTrastuzumabWomananticancer researchbrain metabolismcancer cellcell motilityclinical applicationclinical careclinically relevantdrug developmenteffective therapyefficacy testingimprovedin vivoinhibitor/antagonistinsightkinase inhibitorloss of functionmalignant breast neoplasmmembermortalitynext generation sequencingnovelnovel therapeuticsoverexpressionpalliativetargeted treatmenttherapeutic targettumor progressionvector control
项目摘要
Among 1.6 million women diagnosed with breast cancer every year, about 10-16% develop brain metastasis.
Even with the most advanced clinical care, patients with brain metastasis have a devastating <20% one-year
survival. At present, no effective drug treatment exists for patients with refractory breast cancer metastatic to
the brain. Therefore, novel and effective therapies are urgently needed for this population. Unfortunately,
developing effective therapies for brain metastasis is largely hampered by a lack of in-depth understanding of
the basic mechanisms of brain metastasis, which could guide drug development and clinical trials. To
surmount the challenge, we have performed an unprecedented in vivo screen of the human kinome to uncover
novel kinases that promote breast cancer brain metastasis in mice, because kinases are at the central nodes
of cancer cell signaling networks critical for cancer progression/metastasis and are druggable as therapeutic
targets. Among the top candidate kinases associated with aggressive brain metastasis we identified, Mitogen-
Activated Protein Kinase 12 (MAPK12, also known as p38γ) was not previously known to play roles in brain
metastasis but is overexpressed in highly aggressive human breast cancers, and patients with MAPK12 high-
expressing breast cancers have higher incidences of brain metastasis later on. Therefore, we performed
experimental brain metastasis assays using MAPK12-overexpressing breast cancer cells, and validated that
MAPK12 indeed promotes brain metastasis in animals. MAPK12 is a member of the MAPK family and its
overexpression increases cancer cell motility and invasion. Excitingly, we identified that MAPK12 is located at
the "hub" of a signaling network of brain metastasis-enriched kinases that enhances brain metastatic cells’
utilization of lactate as an energy source for outgrowth in the brain. Furthermore, MAPK12 is targetable with
available inhibitors that are used in the clinic for other diseases. Here, we hypothesize that activation/
overexpression of MAPK12 coordinates signaling pathways in breast cancer cells to promote brain metastasis,
and MAPK12 may be effectively inhibited by using clinically applicable kinase inhibitors. The major goals of
this proposal are 1) Determine the functional roles of MAPK12 in spontaneous brain metastasis and in immune
competent brain metastasis models, and further validating their clinical relevance; 2) Investigate novel
mechanisms of MAPK12-mediated breast cancer brain metastasis by focusing on how MAPK12-activated
brain metastatic cancer cells efficiently use lactate as an energy source for adaptation and outgrowth in the
brain; 3) Explore the potential of MAPK12 as a therapeutic target for the treatment and/or prevention of breast
cancer brain metastasis. The successful completion of these studies will bring about new understanding of
breast cancer brain metastasis and the first generation of effective brain metastasis-targeted therapies.
Ultimately, our findings will be smoothly translated to clinical trials, leading to new and better treatments for
breast cancer brain metastasis patients in dire search of hope.
在每年被诊断出患有乳腺癌的160万妇女中,大约10-16%的脑转移。
即使拥有最先进的临床护理,脑转移患者的毁灭性<20%一年
生存。目前,难治性乳腺癌转移性患者尚无有效的药物治疗
大脑。因此,迫切需要对该人群进行新颖有效的疗法。很遗憾,
缺乏对脑转移的有效疗法,这在很大程度上受到了对
脑转移的基本机制,可以指导药物开发和临床试验。到
克服挑战,我们进行了一个前所未有的人类Kinome的体内屏幕
促进小鼠乳腺癌脑转移的新型激酶,因为激酶在中心节点
癌细胞信号网络对癌症进展/转移至关重要,可作为治疗可吸毒
目标。在与侵袭性脑转移相关的顶级候选激酶中,我们确定了有丝分裂原的
激活的蛋白激酶12(MAPK12,也称为p38γ)以前尚不知道在脑中起作用
转移,但在高度侵略性的人乳腺癌中过表达,MAPK12高 -
表达乳腺癌的脑转移较高的乳腺癌发作。因此,我们执行了
使用MAPK12过表达乳腺癌细胞的实验性脑转移测定,并验证了
MAPK12确实促进了动物的脑转移。 MAPK12是MAPK家族及其的成员
过表达增加了癌细胞的运动和侵袭。令人兴奋的是,我们确定MAPK12位于
脑转移富含激酶的信号网络的“枢纽”,可增强脑转移细胞”
利用鞋底作为大脑生长的能源。此外,MAPK12是针对的
可用于其他疾病的诊所中使用的可用抑制剂。在这里,我们假设激活/
MAPK12的过表达使乳腺癌细胞中的信号通路促进脑转移,
通过使用临床适用的激酶抑制剂可以有效抑制MAPK12。主要目标
该提议是1)确定MAPK12在赞助大脑转移和免疫中的功能作用
有能力的脑转移模型,并进一步验证其临床相关性; 2)研究小说
MAPK12介导的乳腺癌脑转移的机制通过关注MAPK12激活的方式
脑转移性癌细胞有效地使用缝隙作为适应和生长的能源
脑; 3)探索MAPK12作为治疗和/或预防乳房的治疗靶标的潜力
癌症脑转移。这些研究的成功完成将带来对
乳腺癌脑转移和有效的脑转移靶向疗法的第一代。
最终,我们的发现将顺利地转化为临床试验,从而为您提供新的更好的治疗方法
乳腺癌脑转移患者在恐惧中寻找希望。
项目成果
期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Tumor microenvironment as a therapeutic target in cancer.
- DOI:10.1016/j.pharmthera.2020.107753
- 发表时间:2021-05
- 期刊:
- 影响因子:13.5
- 作者:Xiao Y;Yu D
- 通讯作者:Yu D
Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention.
针对雌激素受体阴性乳腺癌预防的异常 p70S6K 激活。
- DOI:10.1158/1940-6207.capr-17-0106
- 发表时间:2017
- 期刊:
- 影响因子:0
- 作者:Wang,Xiao;Yao,Jun;Wang,Jinyang;Zhang,Qingling;Brady,SamuelW;Arun,Banu;Seewaldt,VictoriaL;Yu,Dihua
- 通讯作者:Yu,Dihua
Oncogenic Kinase-Induced PKM2 Tyrosine 105 Phosphorylation Converts Nononcogenic PKM2 to a Tumor Promoter and Induces Cancer Stem-like Cells.
- DOI:10.1158/0008-5472.can-17-2726
- 发表时间:2018-05-01
- 期刊:
- 影响因子:11.2
- 作者:Zhou Z;Li M;Zhang L;Zhao H;Şahin Ö;Chen J;Zhao JJ;Songyang Z;Yu D
- 通讯作者:Yu D
Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases.
- DOI:10.1126/scitranslmed.aaz5387
- 发表时间:2020-05-27
- 期刊:
- 影响因子:17.1
- 作者:Zhang L;Yao J;Wei Y;Zhou Z;Li P;Qu J;Badu-Nkansah A;Yuan X;Huang YW;Fukumura K;Mao X;Chang WC;Saunus J;Lakhani S;Huse JT;Hung MC;Yu D
- 通讯作者:Yu D
The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1.
- DOI:10.1016/j.ccell.2021.11.002
- 发表时间:2022-01-10
- 期刊:
- 影响因子:50.3
- 作者:Li H;Xiao Y;Li Q;Yao J;Yuan X;Zhang Y;Yin X;Saito Y;Fan H;Li P;Kuo WL;Halpin A;Gibbons DL;Yagita H;Zhao Z;Pang D;Ren G;Yee C;Lee JJ;Yu D
- 通讯作者:Yu D
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dihua Yu其他文献
Dihua Yu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dihua Yu', 18)}}的其他基金
Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer
探索雌激素受体阴性乳腺癌免疫预防的新策略
- 批准号:
10583390 - 财政年份:2023
- 资助金额:
$ 43.26万 - 项目类别:
Exploring the Function of MHC-II/Lag3 Axis in Brain Metastasis to Develop Novel Therapeutic Strategies
探索 MHC-II/Lag3 轴在脑转移中的功能以开发新的治疗策略
- 批准号:
10659242 - 财政年份:2022
- 资助金额:
$ 43.26万 - 项目类别:
Combating Breast Cancer Brain Metastasis by Blocking the Two-Pronged Driver Kinase Function of CDK5
通过阻断 CDK5 的双管驱动激酶功能来对抗乳腺癌脑转移
- 批准号:
10380589 - 财政年份:2019
- 资助金额:
$ 43.26万 - 项目类别:
Combating Breast Cancer Brain Metastasis by Blocking the Two-Pronged Driver Kinase Function of CDK5
通过阻断 CDK5 的双管驱动激酶功能来对抗乳腺癌脑转移
- 批准号:
9904595 - 财政年份:2019
- 资助金额:
$ 43.26万 - 项目类别:
Combating Breast Cancer Brain Metastasis by Blocking the Two-Pronged Driver Kinase Function of CDK5
通过阻断 CDK5 的双管驱动激酶功能来对抗乳腺癌脑转移
- 批准号:
10615611 - 财政年份:2019
- 资助金额:
$ 43.26万 - 项目类别:
Co-targeting PDAC tumor cells and the microenvironment to succeed in EGFR/ErbB2-targeted therapy
共同靶向 PDAC 肿瘤细胞和微环境以成功实现 EGFR/ErbB2 靶向治疗
- 批准号:
9438639 - 财政年份:2018
- 资助金额:
$ 43.26万 - 项目类别:
Inhibition of brain metastasis by blocking MAPK12 driver kinase functions
通过阻断 MAPK12 驱动激酶功能抑制脑转移
- 批准号:
9308550 - 财政年份:2017
- 资助金额:
$ 43.26万 - 项目类别:
Inhibition of brain metastasis by blocking MAPK12 driver kinase functions
通过阻断 MAPK12 驱动激酶功能抑制脑转移
- 批准号:
10025581 - 财政年份:2017
- 资助金额:
$ 43.26万 - 项目类别:
Target p70S6K for Chemodietary Prevention/Early Intervention of ER- Breast Cancer
用于 ER-乳腺癌化学饮食预防/早期干预的靶标 p70S6K
- 批准号:
9215654 - 财政年份:2015
- 资助金额:
$ 43.26万 - 项目类别:
Metabolic Deregulation by 14-3-3 in Mammary Tumor Progression
14-3-3 在乳腺肿瘤进展中的代谢失调
- 批准号:
7962744 - 财政年份:2010
- 资助金额:
$ 43.26万 - 项目类别:
相似国自然基金
大型野生动物对秦岭山地森林林下植物物种组成和多样性的影响及作用机制
- 批准号:32371605
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
闸坝建设对河口大型底栖动物功能与栖息地演变的影响-以粤西鉴江口为例
- 批准号:42306159
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
降水变化下土壤动物协作效应对土壤有机质形成过程的影响
- 批准号:42307409
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
城市化对土壤动物宿主-寄生虫关系的影响机制研究
- 批准号:32301430
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
两栖动物(蛙类)对新型卤代有机污染物的生物富集及其对污染物环境迁移影响的研究
- 批准号:42307349
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Executive functions in urban Hispanic/Latino youth: exposure to mixture of arsenic and pesticides during childhood
城市西班牙裔/拉丁裔青年的执行功能:童年时期接触砷和农药的混合物
- 批准号:
10751106 - 财政年份:2024
- 资助金额:
$ 43.26万 - 项目类别:
A HUMAN IPSC-BASED ORGANOID PLATFORM FOR STUDYING MATERNAL HYPERGLYCEMIA-INDUCED CONGENITAL HEART DEFECTS
基于人体 IPSC 的类器官平台,用于研究母亲高血糖引起的先天性心脏缺陷
- 批准号:
10752276 - 财政年份:2024
- 资助金额:
$ 43.26万 - 项目类别:
Endothelial Cell Reprogramming in Familial Intracranial Aneurysm
家族性颅内动脉瘤的内皮细胞重编程
- 批准号:
10595404 - 财政年份:2023
- 资助金额:
$ 43.26万 - 项目类别:
Dravet Syndrome Anti-Epileptic Control by Targeting GIRK Channels
通过针对 GIRK 通道进行 Dravet 综合征抗癫痫控制
- 批准号:
10638439 - 财政年份:2023
- 资助金额:
$ 43.26万 - 项目类别: